Keywords: ahus; Transplantation-associated thrombotic microangiopathy (TA-TMA); aHUS; Eculizumab;
مقالات ISI ahus (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ahus; ADAMTS13; disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS; atypical hemolytic uremic syndrome; BU; Bethesda units; CF; complement factor; CFHR; complement factor H-related; HUS; hemolytic uremic syndrome; iTTP; auto
Keywords: ahus; aHUS; atypical hemolytic uremic syndrome; AP; alternative pathway; C3; complement component 3; C5; complement component 5; C3G; C3 glomerulopathy; CFB; complement factor B; CFH; complement factor H; CFI; complement factor I; COMS; complement serology pane
Keywords: ahus; ADA; anti-drug antibodies; AMPK; 5â² adenosine monophosphate-activated protein kinase; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; APC; antigen presenting cells; AT; anaphylatoxin; BTK; Bruton's tyrosine kinase; C1q
Keywords: ahus; Atypical hemolytic uremic syndrome; Complement; Eculizumab; Terminal complement inhibitor; Thrombotic microangiopathy; AH50; Alternative pathway function; TMA; Thrombotic microangiopathy; HUS; Hemolytic uremic syndrome; aHUS; Atypical HUS; LDH; Lactate de
Keywords: ahus; aHUS; HUS; kidney; monoclonal gammopathy; M protein; thrombotic microangiopathy; TTP;
Keywords: ahus; ABMR; Antibody mediated rejection; aHUS; Atypical hemolytic syndrome; AP; Alternative pathway; DBD; Deceased brain dead; DCD; Deceased cardiac death; DSA; Donor specific antibodies; C1-INH; C1-inhibitor; C3; Complement component C3; CDC; Complement-depend
Keywords: ahus; Transgenic mouse; C3G; aHUS; PNH; Complement;
Keywords: ahus; aHUS; children; eculizumab; kidney disease; pediatric; thrombotic microangiopathy;
Keywords: ahus; PNH; aHUS; CAD; Complement therapeutics; C5; Eculizumab; C3; Compstatin
Keywords: ahus; aHUS; hemolytic uremic syndrome; CP; classical pathway; LP; lectin pathway; AP; alternative pathway; FDA; Food and Drug Administration; EMA; European Medicines Agency; PNH; paroxysmal nocturnal hemoglobinuria; C5D; C5 deficient; NHS; normal human serum; E
Keywords: ahus; AChR; acetylcholine receptor; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; AMR; antibody-mediated rejection; ANCA; anti-neutrophil cytoplasmic antibody; AP; alternative pathway; C1-INH; C1 esterase inhibitor; C3GN; C3 g
Keywords: ahus; Eculizumab; Complement therapeutics; PNH; aHUS; C3; C5; Compstatin;
Keywords: ahus; CVF; cobra venom factor; rCVF; recombinant CVF; hCVF; humanized CVF; MAC; membrane attack complex; PNH; paroxysmal nocturnal hemoglobinuria; MI/RI; myocardial ischemia reperfusion injury; GI/RI; gastrointestinal ischemia reperfusion injury; AMD; age-relat
Keywords: ahus; aHUS; TTP; ADAMTS13 activity; Complement activation; Thrombotic microangiopathy;
Keywords: ahus; AP; alternative pathway; aHUS; atypical hemolytic syndrome; ADAMTS13; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; AP; alternative pathway; CCP; complement control protein domain; DDD; dense deposit disease; DGKE; dia
Properdin: A multifaceted molecule involved in inflammation and diseases
Keywords: ahus; aHUS; atypical hemolytic uremic syndrome; AAA; abdominal aortic aneurysm; AAV; ANCA-associated vasculitis; AMD; age-related macular degeneration; AMR; antibody-mediated rejection; ANCA; anti-neutrophil cytoplasmic antibody; AP; alternative pathway; APC; a
Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome
Keywords: ahus; aHUS; atypical hemolytic uremic syndrome; aPL; antiphospholipid antibodies; APS; antiphospholipid syndrome; CRF; complement regulatory factors; CTD; connective tissue diseases; ELISA; enzyme-linked immunosorbent assays; FH; factor H; HRP; hydrogen peroxid
Theranostic of biopharmaceuticals
Keywords: ahus; α3Gal; galactose-α1,3-galactose; ADA; anti-drug antibody; aHUS; atypical hemolytic uremic syndrome; ARIC; ADA-related immune complex; CEP17; centromere of chromosome 17; CCP; cyclic citrullinated peptide; CTLA-4; cytotoxic T-lymphocyte-associated protei
Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders
Keywords: ahus; aHUS; atypical haemolytic uremic syndrome; AMD; age-related macular degeneration; aPL; anti-phospholipid antibodies; C3-NeF; C3- nephritic factor; CCP; complement control protein; CEP; Carboxyethylpyrrole; CL; Cardiolipin; CNV; copy number variation; CR;
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
Keywords: ahus; Complement activation; C5a blockade; Trypsin; Thrombin; Eculizumab; aHUS; atypical hemolytic uremic syndrome; APH50; 50% haemolytic complement activity of alternative pathway; C3N; C3 glomerulonephritis; CH50; 50% haemolytic complement activity of classic
Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action
Keywords: ahus; aHUS; atypical hemolytic and uremic syndrome; C5; complement protein C5; CDR; complementarity determining region; CVF; cobra venom factor; DMSO; dimethylsulfoxyde; ECZ; eculizumab; Fab; fragment antigen binding; Fv; fragment variable; mAb; monoclonal anti
Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)
Keywords: ahus; aHUS; Complement; Treatment; Genetics;
The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome
Keywords: ahus; AP; alternative pathway; aHUS; atypical hemolytic uremic syndrome; CP; classical pathway; CR1; complement receptor 1; DAF; decay accelerating factor; DDD; dense deposit disease; EM; electron microscopy; FB; factor B; FD; factor D; FH; factor H; FI; factor
Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome
Keywords: ahus; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; ANOVA; analysis of variance; C3; complement component 3; C3; C3 gene; C3G; C3-glomerulopathy; C4; complement component 4; C4; C4 gene; CGH; comparative genomic hybridization;
Interaction of Shiga toxin 2 with complement regulators of the factor H protein family
Keywords: ahus; EHEC; enterohemorrhagic Escherichia coli; FH; factor H; FHL-1; factor H-like protein 1; FHR-1; factor H-related protein 1; FI; factor I; HUS; hemolytic uremic syndrome; aHUS; atypical HUS; MCP; membrane cofactor protein; SCRs; short consensus repeats; Stx
Contribution of complement factor H Y402H polymorphism to sudden sensorineural hearing loss risk and possible interaction with diabetes
Keywords: ahus; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; CFH; complement factor H; CI; confidence interval; CRP; C-reactive protein; MPGN2; membranoproliferative glomerulonephritis type II; NILS-LSA; National Institute for Longevit
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS
Keywords: ahus; aHUS; Complement; Genetic polymorphisms;
Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?
Keywords: ahus; HUS; haemolytic uraemic syndrome; TMA; thrombotic microangiopathy; ECs; endothelial cells; AP; alternative pathway; CP; classical pathway; MAC; membrane attack complex; CFH; complement factor H; SCRs; short consensus repeats; CFI; complement factor I; DAF
Complement Factor H-ligand interactions: Self-association, multivalency and dissociation constants
Keywords: ahus; AMD; age-related macular degeneration; aHUS; atypical haemolytic uraemic syndrome; KD; dissociation constant; CRP; C-reactive protein; FH; Factor H; SCR; short complement regulator; Analytical ultracentrifugation; Surface plasmon resonance; X-ray scatteri